TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01750918
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
Study: NCT01145508
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04030195
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
Study: NCT00022932
Drug: Iodine-131 Anti-B1 Antibody
Normalized name: Iodine-131 anti-b1 antibody
DrugBank: Tositumomab I-131 (DB17991)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00468715
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00548899
Drug: Nexavar (Sorafenib)
Normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
Study: NCT01861197
Drug: Dovitinib
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib 500mg daily for 5 days on/ 2 day off until progression
Study: NCT02593929
Drug: ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00934895
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
Study: NCT00934895
Drug: abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
Study: NCT01195025
Drug: acetated Ringers
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Ringer acetate 20 ml/kg over 30 min
Study: NCT01195025
Drug: colloid
Normalized name: tin colloid
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of starch 10 ml/kg over 30 min
Study: NCT01195025
Drug: colloid+acetated Ringer
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
Study: NCT01609933
Drug: pegylated interferon alpha-2a (pegIFN)
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegIFN alpha-2a (syringe)
Study: NCT01609933
Drug: Ribavirin (RBV)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (tablets)
Study: NCT01455194
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
Study: NCT03275870
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
Study: NCT01633177
Drug: Omega-3 fatty acid (fish oil)
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study: NCT01633177
Drug: Fish oil placebo
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil placebo
Study: NCT04550962
Drug: Dupilumab SAR231893
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution Route of administration: subcutaneous~Dose regimen:
Study: NCT00359762
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study: NCT00359762
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet (titrated to maximally tolerated dose), once daily
Study: NCT01902017
Drug: Ketotifen
Normalized name: Ketotifen
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg PO bid
Study: NCT00051844
Drug: Capravirine
Normalized name: Capravirine
DrugBank: Capravirine (DB08502)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01172938
Drug: Apremilast 20mg
Normalized name: APREMILAST 20MG ORAL TAB
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 20 mg twice daily, orally
Study: NCT01172938
Drug: Apremilast 30mg
Normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 30 mg twice daily, orally
Study: NCT01172938
Drug: Placebo + 20 mg Apremilast
Normalized name: apremilast 20 MG
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo + 20 mg Apremilast
Study: NCT01172938
Drug: Placebo + 30 mg Apremilast
Normalized name: apremilast 30 MG
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo + 30 mg Apremilast
Study: NCT01411189
Drug: Menthol
Normalized name: Menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL NPO-11 in prefilled syringe
Study: NCT03311126
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.
Study: NCT03311126
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
Study: NCT00215150
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline augmentation with ziprasidone
Study: NCT00215150
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
Study: NCT00885443
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
Study: NCT00165724
Drug: Donepezil Hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01554046
Drug: Methylphenidate- Ritalin IR (Immediate Release)
Normalized name: methylphenidate Oral Tablet [Ritalin]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~* Ages 6-12, up to 25Kg - 35mg maximum per day.~* Ages 6-12, above 25Kg - 50mg maximum per day.~* Ages 12-65, above 25Kg - 80mg maximum per day.
Study: NCT02256111
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01910844
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
Study: NCT00885443
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
Study: NCT00077454
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT00077454
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01810887
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
Study: NCT01810887
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
Study: NCT03914352
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
Study: NCT02850250
Drug: Cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
Study: NCT00716521
Drug: zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose, 5 mg zolpidem
Study: NCT00716521
Drug: zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose, 10 mg zolpidem
Study: NCT00430040
Drug: Carvedilol Controlled Release (CR)
Normalized name: carvedilol Extended Release Oral Capsule
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80
Study: NCT00430040
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
Study: NCT02857712
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
Study: NCT04430348
Drug: PTX-35
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody PTX-35
Study: NCT03644576
Drug: ozanimod
Normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ozanimod
Study: NCT03644576
Drug: Pseudoephedrine
Normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudoephedrine
Study: NCT03644576
Drug: ozanimod placebo
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ozanimod placebo
Study: NCT03515798
Drug: Pembrolizumab Injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
Study: NCT03515798
Drug: neoadjuvant EC-paclitaxel chemotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
Study: NCT01557010
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, oral administration, Placebo
Study: NCT02537860
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each patient will receive 75 mg bupivacaine during PVB
Study: NCT03486236
Drug: VX-440
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-440 was administered in TC with TEZ and IVA.
Study: NCT03486236
Drug: TEZ
Normalized name: Otezla
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
Study: NCT03486236
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
Study: NCT03361501
Drug: CaPre
Normalized name: Caprelsa
DrugBank: Capreomycin (DB00314)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 x 1 g capsules administered orally once daily for 26 weeks
Study: NCT03139370
Drug: KITE-718
Normalized name: KITE-222
DrugBank: KITE-222 (DB17195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
Study: NCT03139370
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04206787
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: drug
Study: NCT02477696
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral acalabrutinib as stated in arm description.
Study: NCT02477696
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive oral ibrutinib as stated in arm description.
Study: NCT03598998
Drug: Pralatrexate
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00427414
Drug: liposomal daunorubicin citrate
Normalized name: daunorubicin citrate liposome
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
Study: NCT00848991
Drug: Precedex
Normalized name: Precedex
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
Study: NCT00848991
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: evaulation of propofol for emergence from anesthesia
Study: NCT02015819
Drug: flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00981435
Drug: Artificial Tears
Normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artificial saline tears to lasered eye 4 times/day for 4.5 days
Study: NCT03752905
Drug: PTR-01
Normalized name: PTR-01
DrugBank: PTR-01 (DB17900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human collagen 7 (rC7)
Study: NCT00013884
Drug: T-20
Normalized name: T-2000
DrugBank: ALT-2074 (DB05631)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05385562
Drug: Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate
Normalized name: Nystatin and Triamcinolone Acetonide Cream
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: formulated with sodium hyaluronate and chondroitin sulfate
Study: NCT05385562
Drug: Triamcinolone Acetonide alone
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide alone
Study: NCT04616586
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 11 mg/kg IV administered over 1 hour
Study: NCT01886664
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01886664
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00035893
Drug: poly I-poly C12U
Normalized name: poly I:C
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-400 mg IV infusions 2x/week for 64 weeks
Study: NCT01860170
Drug: Cohort 1-Bortezomib (Velcade ®)
Normalized name: bortezomib Injection [Velcade]
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Study: NCT01860170
Drug: Cohort 2-Bortezomib (Velcade ®)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Study: NCT01860170
Drug: Cohort 3-Bortezomib (Velcade ®)
Normalized name: bortezomib 3.5 MG
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Study: NCT00497224
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
Study: NCT00759577
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg and 10 mg, oral once daily
Study: NCT03563534
Drug: Silver Diamine Fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
Study: NCT03002506
Drug: Ceftolozane/tazobactam
Normalized name: CEFTOLOZANE/TAZOBACTAM
DrugBank: Tazobactam (DB01606)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 2 grams/1 gram intravenously administered over 60 minutes.